AXQ Capital LP Has $270,000 Holdings in AngioDynamics, Inc. $ANGO

AXQ Capital LP boosted its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 34.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,231 shares of the medical instruments supplier’s stock after buying an additional 7,011 shares during the quarter. AXQ Capital LP owned about 0.07% of AngioDynamics worth $270,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ANGO. Armistice Capital LLC lifted its position in shares of AngioDynamics by 140.1% in the first quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier’s stock worth $19,663,000 after buying an additional 1,222,000 shares during the last quarter. Nuveen LLC bought a new position in shares of AngioDynamics in the 1st quarter valued at approximately $10,803,000. Phocas Financial Corp. acquired a new stake in AngioDynamics in the 1st quarter worth approximately $3,177,000. Informed Momentum Co LLC acquired a new stake in AngioDynamics in the 1st quarter worth approximately $3,151,000. Finally, Bastion Asset Management Inc. boosted its position in AngioDynamics by 46.5% during the second quarter. Bastion Asset Management Inc. now owns 959,043 shares of the medical instruments supplier’s stock worth $9,810,000 after purchasing an additional 304,217 shares during the period. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Trading Up 2.9%

Shares of NASDAQ ANGO opened at $12.30 on Tuesday. The firm has a market capitalization of $506.76 million, a price-to-earnings ratio of -15.77 and a beta of 0.74. AngioDynamics, Inc. has a one year low of $6.83 and a one year high of $13.50. The business has a fifty day simple moving average of $11.60 and a 200 day simple moving average of $10.36.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The firm had revenue of $75.71 million for the quarter, compared to the consensus estimate of $72.69 million. During the same quarter in the previous year, the company earned ($0.11) earnings per share. The business’s revenue was up 12.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. On average, research analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ANGO has been the subject of a number of analyst reports. Canaccord Genuity Group boosted their price objective on shares of AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday, October 4th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, AngioDynamics currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Insider Activity

In other AngioDynamics news, SVP Lawrence T. Weiss purchased 10,000 shares of the business’s stock in a transaction on Tuesday, October 21st. The stock was purchased at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the purchase, the senior vice president directly owned 93,597 shares in the company, valued at approximately $1,105,380.57. This trade represents a 11.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James C. Clemmer acquired 10,000 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were bought at an average cost of $11.15 per share, for a total transaction of $111,500.00. Following the completion of the acquisition, the chief executive officer directly owned 882,529 shares of the company’s stock, valued at approximately $9,840,198.35. This represents a 1.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 20,890 shares of company stock worth $239,532. 6.00% of the stock is owned by company insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.